# A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects

> **NCT03230383** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 60 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** PF-06865571
- **DRUG:** PF-06865571
- **DRUG:** PF-06865571
- **DRUG:** PF-06865571
- **DRUG:** PF-06865571
- **DRUG:** PF-06865571
- **DRUG:** PF-06865571
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03230383
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-01
- **Primary completion:** 2018-05-03
- **Final completion:** 2018-05-03
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03230383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03230383, "A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03230383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*